Explore Bioidentical HRT, testosterone & pellets
Its a glucagon-like peptide-1 (GLP-1) receptor agonist, which means the drug mimics the effects of GLP-1 (a hormone that helps regulate blood sugar levels, appetite, and digestion, among other functions)
Because it activates both, it's often called a "dual agonist." The FDA has described tirzepatide (brand name Zepbound) as the first medication of its kind to activate both of these receptors for weight management, and it was approved for that use in November 2023
PCOS also called polyendocrine metabolic ovarian syndrome (PMOS) in recent medical literature following a 2026 global consensus rename (Teede et al
GLP-1 Orders for Overweight or Obese Patients Q1 2026 Quarterly rates per 100,000 of patients with an overweight or obese BMI receiving a prescription, dispense, or reporting starting a GLP-1 medication
It turned out ok